Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 26;90(1):5-10.
doi: 10.23750/abm.v90i1.6563.

Contact dermatitis due to transdermal therapeutic systems: a clinical update

Paolo Romita  1 , Caterina Foti, Gianfranco Calogiuri, Stefania Cantore, Andrea Ballini, Gianna Dipalma, Francesco Inchingolo
Affiliations
Review

Contact dermatitis due to transdermal therapeutic systems: a clinical update

Paolo Romita et al. Acta Biomed. .

Abstract

Transdermal therapeutic systems (TTS) have become a popular method of drug delivery because they allow drugs to be delivered in a rate-controlled manner, avoiding first-pass metabolism and the fluctuating plasma concentrations encountered with oral medications. Unfortunately, TTS may provoke adverse skin reactions as irritating contact dermatitis and allergic contact dermatitis: TTS seem to be ideally suited to produce sensitization because they cause occlusion, irritation, due to the repeated placement of the allergen in the same skin location. Since TTS consist of an adhesive, an active pharmaceutical drug and enhancing agents, sensitization may develop owing to one of these three agents. The purpose of this manuscript is to review known responsible allergens of contact dermatitis due to TTS.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Positive patch test to a transdermal therapeutic system containing rivastigmine
Figure 2.
Figure 2.
Allergic contact dermatitis to a transdermal therapeutic system with flurbiprofen for lumbar pain. The culprit allergen was menthol, an excipient used to facilitate the penetration of the active drug
Figure 3.
Figure 3.
Positive patch test to a transdermal therapeutic system caused by an excipient (menthol)
See this image and copyright information in PMC

References

    1. Subedi RK, Oh SY, Chun M-K, Choi H-K. Recent avances in transdermal drug delivery. Arch Pharm Res. 2010;33:339. - PubMed
    1. Ale I, Lachapelle J, Maibach H. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26:920–35. - PubMed
    1. Warshaw EM, Paller AS, Fowler JF, Zirwas MJ. Practical management of cutaneous reactions to the methylphenidate patch: recommendations from a Dermatology Expert Panel Consensus Meeting. Clin Ther. 2008;30:326–37. - PubMed
    1. Perez-Calderon R, Gonzalo-Garijo MA, Rodriguez-Nevado I. Generalized allergic contact dermatitis from nitroglycerin in a transdermal therapeutic system. Contact Dermatitis. 2002;46:303. - PubMed
    1. Machet L, Martin L, Toledano C, et al. Allergic contact dermatitis from nitroglycerin contained in 2 transdermal systems. Dermatology. 1999;198:106. - PubMed

MeSH terms

LinkOut - more resources